The efficacy of novel arylimidamides against Trypanosoma cruzi in vitro

Cristiane Frana Da Silva, Anissa Daliry, Patrcia Bernardino Da Silva, Senol Akay, Moloy Banerjee, Abdelbasset A. Farahat, Mary K. Fisher, Laixing Hu, Arvind Kumar, Zongying Liu, Chad E. Stephens, David W. Boykin, Maria De Nazar Correia Soeiro

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The present study aimed to determine the in vitro biological efficacy and selectivity of 7 novel AIAs upon bloodstream trypomastigotes and intracellular amastigotes of Trypanosoma cruzi. The biological activity of these aromatic compounds was assayed for 48 and 24 h against intracellular parasites and bloodstream forms of T. cruzi (Y strain), respectively. Additional assays were also performed to determine their potential use in blood banks by treating the bloodstream parasites with the compounds diluted in mouse blood for 24 h at 4C. Toxicity against mammalian cells was evaluated using primary cultures of cardiac cells incubated for 24 and 48 h with the AIAs and then cellular death rates were determined by MTT colorimetric assays. Our data demonstrated the outstanding trypanocidal effect of AIAs against T. cruzi, especially DB1853, DB1862, DB1867 and DB1868, giving IC50 values ranging between 16 and 70 nanomolar against both parasite forms. All AIAs presented superior efficacy to benznidazole and some, such as DB1868, also demonstrated promising activity as a candidate agent for blood prophylaxis. The excellent anti-trypanosomal efficacy of these novel AIAs against T. cruzi stimulates further in vivo studies and justifies the screening of new analogues with the goal of establishing a useful alternative therapy for Chagas disease.

Original languageEnglish (US)
Pages (from-to)1863-1869
Number of pages7
Issue number14
StatePublished - Dec 2011


  • Chagas disease
  • Trypanosoma cruzi
  • arylimidamides
  • chemotherapy

ASJC Scopus subject areas

  • Parasitology
  • Animal Science and Zoology
  • Infectious Diseases


Dive into the research topics of 'The efficacy of novel arylimidamides against Trypanosoma cruzi in vitro'. Together they form a unique fingerprint.

Cite this